deucravacitinib


( Last Updated : September 27, 2022)
Generic Name:
deucravacitinib
Project Status:
Received
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Bristol-Myers Squibb Company
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0756-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones

Call for patient/clinician input open29-Aug-22
Call for patient/clinician input closed24-Oct-22
Submission received27-Sep-22
Submission accepted